# A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

Study · id `cardio:ct-nct05355402` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05355402](<https://clinicaltrials.gov/study/NCT05355402>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05355402

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.

## Technical summary

Registry record NCT05355402. Randomized; quadruple masking; primary purpose treatment. Start 2022-05-09 (actual); primary completion 2023-03-22 (actual). Results posted on 2026-04-23.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 154 participants (enrolled count; ClinicalTrials.gov record NCT05355402, source copy `cardio:ctgov-nct05355402-2026-04-23`, retrieved 2026-10-31)
- Started: 2022-05-09 (actual) (ClinicalTrials.gov record NCT05355402, source copy `cardio:ctgov-nct05355402-2026-04-23`, retrieved 2026-10-31)
- Primary completion: 2023-03-22 (actual) (ClinicalTrials.gov record NCT05355402, source copy `cardio:ctgov-nct05355402-2026-04-23`, retrieved 2026-10-31)
- Completion: 2023-12-21 (actual) (ClinicalTrials.gov record NCT05355402, source copy `cardio:ctgov-nct05355402-2026-04-23`, retrieved 2026-10-31)
- Results first posted: 2026-04-23 (ClinicalTrials.gov record NCT05355402, source copy `cardio:ctgov-nct05355402-2026-04-23`, retrieved 2026-10-31)
- Countries: United States; Canada (ClinicalTrials.gov record NCT05355402, source copy `cardio:ctgov-nct05355402-2026-04-23`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05355402-2026-04-23`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
- Condition: Hypertriglyceridemia
- Condition: Atherosclerotic Cardiovascular Disease
- Condition: Severe Hypertriglyceridemia
- Intervention (Drug): Olezarsen
- Intervention (Drug): Placebo
- Lead sponsor: Ionis Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Ionis Pharmaceuticals, Inc. (`cardio:org-ionis-pharmaceuticals-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk (`cardio:pubmed-38587249`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e5fa9d949111472e98f3e8e0d8ddf339dee377e538276c5a057014d82d48aaf3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
